RARE Act
Senate Bill Would Narrow Rare Disease Drug Monopolies to Specific Approved Uses
Legislative Progress
Key Points
- This bill changes how the government grants "exclusivity" to companies that make medicines for rare diseases. Currently, when a company gets a drug approved for a rare disease, they often get 7 years where no one else can sell a drug for that entire disease. This bill limits that protection to only the specific use the drug was approved for.
- Patients with rare diseases could see more treatment options and lower costs. By narrowing the rules, other companies can bring different treatments for the same disease to market much faster instead of being blocked by a broad 7-year "monopoly" on the entire condition.
- This plan aims to fix a problem where one company could stop others from helping patients, even if the new medicine works differently or treats a different part of the illness. It encourages more companies to research rare diseases by making sure one drug doesn't block all others.
- These changes would apply to all rare disease drugs, regardless of when they were first approved or designated. This means even drugs currently on the market would have their protections narrowed to match their specific approved uses.
Impact Analysis
Personal Impact
Life & Work
Smaller biotech and pharmaceutical companies that develop treatments for rare diseases would have an easier path to market. Under current rules, a single company's broad exclusivity over an entire rare disease can block competitors even if they're targeting a different use or mechanism. This change opens the door for smaller firms to pursue niche treatments within the same disease space without waiting out a full 7-year exclusivity period.
Programs
Disabilities
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articles
Health Care Extenders: Key Provisions in the Consolidated Appropriations Act, 2026
The legislation revises how Orphan Drug exclusivity is applied, changing the standard from the 'same disease or condition' to the 'same approved use or indication.' This allows generic competitors to market drugs for new uses or patient populations sooner.
Hospitals testify on proposals to support patients with rare diseases
During a House hearing, medical experts urged Congress to advance the Retaining Access and Restoring Exclusivity (RARE) Act, which would limit orphan drug exclusivity to the approved indication to encourage market competition and lower costs for rare disease treatments.
Rare Disease Month Developments: RPD PRV Program Renewed, Orphan Drug Exclusivity Clarified
The Consolidated Appropriations Act, 2026, codifies the FDA's longstanding interpretation of the Orphan Drug Act by limiting the scope of seven-year exclusivity to the indication ultimately approved, effectively reversing the controversial Catalyst v. Becerra court decision.
Source Information
Document Type
Congressional Bill
Official Title
RARE Act
Data Sources
Sponsor
Analysis generated by AI. Always verify with official sources.